Eurofins Viracor BioPharma Relocates to New Facility to Support Growing Demand for Advanced Testing Services

Eurofins Viracor BioPharma is relocating to a new state-of-the-art facility in Lenexa, Kansas. The 96,000 sq. ft. facility is scheduled for completion in September 2025 and will enhance the company's analytical testing and clinical trial services. The new facility will support the increasing demand for advanced testing services, particularly in sequencing and precision medicine, cell-based assays, and vaccine development. The relocation underscores Eurofins Viracor BioPharma's commitment to investment, innovation, scalability, and operational excellence.

The Taiwanese Conventional PCR (Polymerase Chain Reaction) market has shown robust growth, driven by a thriving healthcare sector and advancements in the biomedical industry. According to a recent report by ResearchAndMarkets.com [1], the market is projected to grow at a CAGR of 2.9% from 2024 to 2030, fueled by rising infectious disease prevalence and an aging population.

The report highlights several key factors contributing to this growth. The Biomedical Industry Innovation Program (BIIP) under the 5+2 Innovative Industries Plan has significantly boosted the sector's revenue, reaching $9.9 billion in 2023, marking a 5% YoY increase. The Development of Biotechnology Act and the National Health Insurance (NHI) system, covering 99.9% of the population, have also driven demand for PCR technology in genetic testing, diagnostics, and pharmaceutical research.

Additionally, strategic collaborations, such as the Taiwan-US Cancer Moonshot Project and ASUS-Roche partnerships, along with government initiatives like the Healthy Taiwan Initiative and Health for All Ages 2030, are accelerating the adoption of PCR technology. These factors are set to make PCR indispensable for precision medicine and diagnostics, driving market growth.

The market is segmented into Consumables & Reagents, Instruments, and Software & Services. Software & Services is expected to experience the highest growth due to increasing demand for advanced data analysis and real-time monitoring. Key players in the market include Thermo Fisher Scientific, Bio-Rad Laboratories, F. Hoffmann-La Roche, Qiagen, Abbott Laboratories, and Becton, Dickinson and Company (BD).

In a related development, Eurofins Viracor BioPharma is relocating to a new state-of-the-art facility in Lenexa, Kansas, scheduled for completion in September 2025. The 96,000 sq. ft. facility will enhance the company's analytical testing and clinical trial services, supporting the growing demand for advanced testing services in sequencing, precision medicine, cell-based assays, and vaccine development.

References:
[1] https://www.globenewswire.com/news-release/2025/08/29/3141311/28124/en/Taiwan-Conventional-PCR-Market-Forecast-Outlook-and-Competitive-Landscape-2025-2030.html